Accuray (NASDAQ:ARAY) Issues Earnings Results, Beats Estimates By $0.01 EPS

Posted by Brenda Bartman on Aug 19th, 2026

Accuray (NASDAQ:ARAY – Get Free Report) posted its quarterly earnings data on Wednesday. The medical equipment provider reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.01, Zacks reports. Accuray had a negative return on equity of 79.43% and a negative net margin of 10.76%.

Accuray Stock Performance

NASDAQ:ARAY traded down $0.02 during mid-day trading on Wednesday, reaching $0.29. The company’s stock had a trading volume of 1,356,032 shares, compared to its average volume of 2,083,886. Accuray has a 12-month low of $0.22 and a 12-month high of $2.10. The firm’s fifty day moving average price is $0.28 and its two-hundred day moving average price is $0.39. The company has a current ratio of 1.42, a quick ratio of 0.66 and a debt-to-equity ratio of 3.21. The stock has a market cap of $35.07 million, a P/E ratio of -0.80 and a beta of 1.39.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on ARAY shares. Jefferies Financial Group cut Accuray from a “buy” rating to a “hold” rating in a research note on Tuesday, May 12th. BTIG Research restated a “neutral” rating on shares of Accuray in a research note on Wednesday, July 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Accuray in a report on Tuesday, August 4th. Two investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Reduce” and a consensus target price of $2.00.

View Our Latest Analysis on Accuray

Institutional Trading of Accuray

A number of institutional investors have recently made changes to their positions in the stock. TCW Group Inc. boosted its stake in shares of Accuray by 29.9% in the 4th quarter. TCW Group Inc. now owns 15,467,952 shares of the medical equipment provider’s stock worth $12,684,000 after buying an additional 3,558,595 shares during the last quarter. TENOR CAPITAL MANAGEMENT Co. L.P. bought a new stake in shares of Accuray in the second quarter worth $2,055,000. Armistice Capital LLC increased its position in Accuray by 35.4% during the fourth quarter. Armistice Capital LLC now owns 4,500,000 shares of the medical equipment provider’s stock valued at $3,711,000 after acquiring an additional 1,176,000 shares during the last quarter. Mackenzie Financial Corp increased its position in Accuray by 76.5% during the fourth quarter. Mackenzie Financial Corp now owns 1,918,086 shares of the medical equipment provider’s stock valued at $1,538,000 after acquiring an additional 831,220 shares during the last quarter. Finally, Citadel Advisors LLC increased its position in Accuray by 9,301.4% during the third quarter. Citadel Advisors LLC now owns 662,499 shares of the medical equipment provider’s stock valued at $1,106,000 after acquiring an additional 669,699 shares during the last quarter. Hedge funds and other institutional investors own 64.08% of the company’s stock.

About Accuray

(Get Free Report)

Accuray Incorporated (NASDAQ: ARAY) is a global medical device company that develops, manufactures and markets innovative radiation therapy solutions for the treatment of cancer. The company’s flagship products include the CyberKnife® System, a robotic radiosurgery platform offering sub-millimeter precision, and the TomoTherapy® System, which combines helical computed tomography (CT) imaging with intensity-modulated radiation therapy (IMRT). More recently, Accuray introduced the Radixact® System, an advanced iteration of its TomoTherapy technology designed to enhance treatment speed and clinical workflow.

Accuray’s suite of products enables clinicians to deliver highly targeted radiation doses while minimizing exposure to surrounding healthy tissue.